Page 11234..»

Archive for the ‘Stem Cell Costa Rica’ Category

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of…

Monday, June 7th, 2021

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous04.06.2021 / 19:32 The issuer is solely responsible for the content of this announcement.

Media Release

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, Mass., USA and WILMINGTON, Del., USA - June 4, 2021 - MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ:INCY) today announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi(R)) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A total of 80 out of 81 enrolled study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis at approximately three years follow-up (>=35 months).[1] The long-term analysis, as assessed by an independent review committee (IRC), showed that patients treated with tafasitamab plus lenalidomide had an overall response rate (ORR) of 57.5% (95% CI = 45.9%, 68.5%; 46 out of 80 patients), including a complete response (CR) rate of 40% (32 out of 80 patients). Additionally, the median duration of response (DoR) was 43.9 months (95% CI = 26.1, NR), with a median overall survival (OS) of 33.5 months (95% CI = 18.3, NR) and median progression free survival (PFS) of 11.6 months (95% CI = 6.3, 45.7).

These data (abstract #7513) are available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021, and will be presented as a poster and poster discussion in the Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia session.

"The three-year efficacy data, combined with the safety and tolerability profile of tafasitamab, further support a therapeutic option for patients with relapsed or refractory DLBCL who are ineligible for transplant - a traditionally difficult-to-treat population," said Gilles Salles, M.D., Ph.D., Lymphoma Service Chief at Memorial Sloan Kettering Cancer Center, and lead investigator of the L-MIND study*. "I am encouraged to see the confirmed favorable outcome of patients in the L-MIND study, which suggest that this combination treatment regimen could potentially offer a paradigm shift and long-term disease control."

The new results - based on an October 30, 2020 data cut-off - build on previous findings showing durable responses and a consistent safety profile of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in autologous stem cell transplantation (ASCT)-ineligible patients with relapsed or refractory DLBCL.

"The three-year follow-up data not only show a durable response and consistent safety profile in patients with relapsed or refractory DLBCL treated with tafasitamab plus lenalidomide, it also suggests the combination could potentially lead to durable remission," said Nuwan Kurukulasuriya, Ph.D., Senior Vice President, Global Head of Medical Affairs, MorphoSys. "We are looking forward to sharing these long-term follow-up findings with the scientific community."

"We are pleased that long-term data from the L-MIND study underscore the clinically-significant durable responses that are possible with tafasitamab plus lenalidomide as a treatment for relapsed or refractory DLBCL," said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte. "We look forward to continuing to build the body of clinical evidence supporting tafasitamab as a treatment option for patients with DLBCL, as well as exploring other potential indications for tafasitamab through our ongoing research and development program."

In July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. This indication is approved under accelerated approval based on ORR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The U.S. approval is based on an efficacy subgroup of 71 patients confirmed by central lab.

The FDA decision represented the first approval of a second-line treatment for adult patients with DLBCL who progressed during or after first-line therapy.

About Diffuse Large B-cell Lymphoma (DLBCL)DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide[2], characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about 40% of patients not responding to initial therapy or relapsing thereafter[3], leading to a high medical need for new, effective therapies[4], especially for patients who are not eligible for an autologous stem cell transplant in this setting.

About L-MINDThe L-MIND trial is a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had at least one, but no more than three prior lines of therapy, including an anti-CD20 targeting therapy (e.g., rituximab), who are not eligible for high-dose chemotherapy or refuse subsequent autologous stem cell transplant. The study's primary endpoint is overall response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion.

For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085.

About TafasitamabTafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi(R) is being co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the European Union has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi(R) is a registered trademark of MorphoSys AG.

XmAb(R) is a registered trademark of Xencor, Inc.

Important Safety Information

What are the possible side effects of MONJUVI?

MONJUVI may cause serious side effects, including:

- Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI.

- Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or any bruising or bleeding.

- Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or develop any signs and symptoms of an infection.

The most common side effects of MONJUVI include:

- Feeling tired or weak

- Diarrhea

- Cough

- Fever

- Swelling of lower legs or hands

- Respiratory tract infection

- Decreased appetite

These are not all the possible side effects of MONJUVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

- Have an active infection or have had one recently.

- Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.

- You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.

- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.

- Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.

You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety Information.

About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the company's proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More information at http://www.morphosys.com or http://www.morphosys-us.com.

Monjuvi(R) is a registered trademark of MorphoSys AG.

Tremfya(R) is a registered trademark of Janssen Biotech, Inc.

About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

MorphoSys Forward-looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Incyte Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding the use of tafasitamab for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), its ongoing clinical development program for tafasitamab, its L-MIND program, its diffuse large B-cell lymphoma (DLBCL) program generally and its further discussions with regulators regarding tafasitamab as a treatment for patients with DLBCL or for any other indication, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company's clinical trials, supply chain, and other third-party providers and development and discovery operations; determinations made by the FDA, European Medicines Agency (EMA), or other regulatory authorities; the Company's dependence on its relationships with its collaboration partners; the efficacy or safety of the Company's products and the products of the Company's collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

*Dr. Salles has provided speaking and advisory services to MorphoSys and Incyte.

Contacts:

[1] Johannes Duell, M.D., et al. Long-term analyses from L-MIND, a Phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract #7513.[2] Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014.[3] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421.[4] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421.

04.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

See the rest here:
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of...

Read More...

Stemedix and the University of South Florida Join Forces – PRNewswire

Sunday, February 14th, 2021

ST. PETERSBURG, Fla., Feb. 8, 2021 /PRNewswire/ -- Stemedix, Inc. is excited to announce its research collaboration agreement with the University of South Florida. This partnership will facilitate advancements in regenerative medicine offerings while helping provide a more precise and personalized approach to existing and future treatment options.

Stemedix, Inc. and the University of South Florida will partner together in an effort to advance the validity of stem cell treatments and overall patient outcomes. Further, this research will broaden the understanding of the full ability of current umbilical cord tissue products in the market and how they scientifically improve cell activity in the regenerative and healing process.

The goal of this collaboration is to collect the appropriate data to create targeted and enhanced protocols that may then be used under a Research IND (investigational new drug) to achieve FDA approval.

"We are excited to be a contributing part of the research and advancement efforts to create protocols that will provide optimal patient outcomes. The groundwork we are doing today will help to create advanced targeted therapies to present to the FDA for approval," said Fred Palmer, director of operations, at Stemedix, Inc. "Stemedix is proud to be partnering with this prestigious university to bring about exciting opportunities in the field of regenerative medicine for patients seeking an alternative option that will address their needs personally."

Stemedix, Inc. has rooted in the foundation that regenerative medicine is the future and will continue its path of advancement for the medical industry in the service of their patients. Parallel to this partnership, they have established an actively updated blog site with scientific summaries of industry studies led by their Ph.D. team at https://www.stemedix.com/blog

Stemedix, Inc. is a Regenerative Medicine and Wellness provider headquartered in St. Petersburg, FL with other locations throughout the U.S. and Costa Rica. Stemedix was founded to provide access to patients seeking alternative options for their degenerative, chronic pain, or autoimmune condition. With an eight-year footprint in the industry of Regenerative Medicine, Stemedix has maintained its authenticity as an ethical and compassionate provider by focusing on patients' safety and positive end to end experience while following science in an effort to create optimal treatment outcomes. The Stemedix difference is the quality of our care coordinators, providers, and understanding of the importance of having a worry-free and safe experience.

To speak to one of our Care Coordinators call 800-531-0831 or visit our website http://www.stemedix.com

Related Images

stemedix-inc.png Stemedix, Inc

university-of-south-florida.jpg University Of South Florida USF Logo

SOURCE Stemedix, Inc.

Visit link:
Stemedix and the University of South Florida Join Forces - PRNewswire

Read More...

Exosome therapeutic Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper – KSU…

Sunday, February 14th, 2021

Exosome therapeutic Market Report Provides Future Development Possibilities By Key Players, Key Drivers, Competitive Analysis, Scope, And Key Challenges Analysis. The Reports Conjointly Elaborate The Expansion Rate Of The Industry Supported The Highest CAGR And Global Analysis. This Report Providing An In Depth And Top To Bottom Analysis By Market Size, Growth Forecast By Applications, Sales, Size, Types And Competitors For The Creating Segment And The Developing Section Among The Exosome therapeutic Market. Market Expansion Worldwide With Top Players Future Business Scope and Investment Analysis Report

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

View original post here:
Exosome therapeutic Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper - KSU...

Read More...

Exosome therapeutic Market to Deliver Prominent Growth & Striking Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 – The…

Sunday, February 14th, 2021

In this credible Exosome therapeutic Market report, a study about market overview is performed by considering market drivers, market restraints, opportunities and challenges. Moreover, this report contains significant data, current market trends, market environment, technological innovation, upcoming technologies and the technical progress in the allied industry. This is the most relatable, exclusive, and commendable market research report formulated by focusing on definite business needs. The competitive analysis conducted in this report covers strategic profiling of key market players, their core competencies, and competitive landscape. To gain meaningful market insights and thrive in this competitive market place, this Exosome therapeutic Market research report plays a key role.

Exosome therapeutic Market report also makes available major statistics on the market status of global and regional manufacturers and is a supportive source for companies and individuals interested in the industry. The careful efforts accompanied with integrated approaches gives an output of such excellent market research report that drives the decision making process of the business. This report endows with a profound overview of product specification, technology, product type and production analysis by considering most important factors such as revenue, cost, and gross margin. With this influential Exosome therapeutic Market analysis report businesses can successfully make decisions about business strategies to achieve maximum return on investment (ROI).

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

The rest is here:
Exosome therapeutic Market to Deliver Prominent Growth & Striking Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 - The...

Read More...

Exosome Therapeutic Market Is Set To Experience Revolutionary Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International…

Tuesday, November 10th, 2020

The large scale Exosome Therapeutic Market research report recognizes and analyses the emerging trends along with major drivers, challenges and opportunities in the market. Following aspects are kept into view while formulating this global Exosome Therapeutic Market report and include the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific & Middle East & Africa. The market size, revenue generated from the sales and technologies by various application segments are also evaluated in this Exosome Therapeutic Market report. The report estimates 2020-2027 market development trends for industry.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Exosome Therapeutic Market Is Set To Experience Revolutionary Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International...

Read More...

Exosome Therapeutic Market Analysis over Numerous Prominent || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,…

Tuesday, November 10th, 2020

Analysis and discussion of important industry trends, market size, and market share are estimated in the Exosome Therapeutic Market report. This market research report identifies and analyses the emerging trends along with major drivers, restraints, challenges and opportunities in the market. Businesses can have an idea about complete background analysis of the industry which includes an assessment of the parental market. Furthermore, it works to determine the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. This global Exosome Therapeutic Market document takes into consideration diverse segments of the market analysis that todays business ask for.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

See the rest here:
Exosome Therapeutic Market Analysis over Numerous Prominent || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,...

Read More...

Exosome Therapeutic Market is Thriving with Rising Latest Trends || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,…

Saturday, October 17th, 2020

For an outstanding business growth, companies must take up market research report service which is vital in todays market place. An influential Exosome Therapeutic Market report also offers top to bottom examination of the market for estimating income, return on investment (ROI) and developing business strategies. This market research report helps out the business in every sphere of trade to take the unmatched decisions, to tackle the toughest business questions and diminish the risk of failure. The industry report highlights general market conditions, estimates market share and possible sales volume of industry. The facts and figures described in this Exosome Therapeutic Market document aids industry in taking sound decisions and planning advertising and sales strategy more successfully.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Read the original post:
Exosome Therapeutic Market is Thriving with Rising Latest Trends || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,...

Read More...

Exosome therapeutic Market Outlook 2020 (COVID 19 Impact Analysis)| Development Trends, Market Demands, Industry Analysis & Forecast by 2027 -…

Saturday, October 17th, 2020

Exosome therapeutic marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

View original post here:
Exosome therapeutic Market Outlook 2020 (COVID 19 Impact Analysis)| Development Trends, Market Demands, Industry Analysis & Forecast by 2027 -...

Read More...

Balanced Salt Solutions Industry Key Drivers, Business Insights And Forecast 2026 |Thermo Fisher Scientific, Lonza Group, Dickinson, EMD Millipore -…

Saturday, October 17th, 2020

The GlobalBalanced Salt SolutionsMarket study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Balanced Salt Solutions market. With tables and figures helping analyze worldwide Global Balanced Salt Solutions market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.The authors of the report have also shed light on the common business tactics adopted by players. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Balanced Salt Solutions market are mapped by the report.In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Balanced Salt Solutions market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Balanced Salt Solutions market and its potential to grow in the years to come.

Get a Balanced Salt Solutions Market Report Sample Copy @https://www.industryandresearch.com/report/Global-Balanced-Salt-Solutions-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201676#samplereport

This comprehensive research on global Balanced Salt Solutions market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Balanced Salt Solutions market. Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand. In addition, the study talks about growth rate, market share and the latest developments in the Balanced Salt Solutions industry around the world. In addition, the special mention of the most important market participants contributes to the importance of the entire market study.Balanced Salt Solutions Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.The research analysts provide an elaborate description of the value chain and its distributor analysis.

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application and regions Moreover, the report also takes into account the governments policies in the evaluation of the market behavior to illustrate the potential opportunities and challenges of the market in each region.The report also covers the recent agreements including merger and acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Balanced Salt Solutions market.This Balanced Salt Solutions Market research is categorized differently considering the various aspects of the market.Additionally, the Balanced Salt Solutions market report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate. Further as the report progresses, a dedicated section on regional overview of the Balanced Salt Solutions market is also included in the report to identify growth of market. ddtnll, th nl l h mrhnv rvw f th rul lr n th Balanced Salt Solutions rkt tgthr d thr mn rfl, W nl, ltt dvnmnt, nd bun ln. h nl vr Balanced Salt Solutions rkt nd t dvnmnt r dffrnt ndutr vrtl wll rgn. t trgt tmtng th urrnt mrkt z nd grwth tntl f th glbl Balanced Salt Solutions rkt r tn uh l ltn nd rrnttv.

Also, the competitive landscape of the Balanced Salt Solutions market is also evaluated at length in the report, to identify and analyze leading service providers. Global Balanced Salt Solutions Market reports provide in-depth analysis of Top Players, Geography, End users, Applications, Competitor analysis, Revenue, Price, Gross Margin, Market Share, Import-Export data, Trends and Forecast.The valuation of the global Balanced Salt Solutions market report represents the approximate calculation of historic verities and statistics which makes this report incredible mention for marketing, industry executives, sales and product managers, and consultants.The report study provides key statistics on the market status of the Balanced Salt Solutions manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report provides in-depth unique Insights with manufacturers, suppliers, distributors, traders, customers, investors and major types as well as applications and forecast period.

Competitive LandscapeThis report includes a study of the marketing and development strategies, along with the product portfolios of the leading companies. It includes the profiles of leading companies such asThermo Fisher Scientific, Lonza Group, Dickinson, EMD Millipore, Becton, Corning Life Sciences, Wheaton, PromoCell, Sigma-Aldrich, Biological. All companies analyzed in the report are studied on the basis of important factors such as market share, market growth, company size, output, sales and income. Furthermore, there is high scope for the entry of new companies, as entry barriers are not well developed. Changing consumer behavior, competition, and trade action are impacting the growth of Balanced Salt Solutions companies.

Balanced Salt Solutions Market Report: Industry Coverage:The Balanced Salt Solutions market report also analyzes the major geographic regions as well as the major countries in these regions. The regions and countries covered in the study include:* North America:The U.S., Canada, Mexico* South America:Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica* Europe:The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark* APAC:China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong* Middle East and Africa:Israel, South Africa, Saudi Arabia

Balanced Salt Solutions Market Segmentation Analysis:-Global Balanced Salt Solutions Market Type Segments:Hanks Balanced Salt Solution, Geys Balanced Salt Solution, Earles Balanced Salt Solution, Dulbeccos Phosphate Buffered Saline, Others

Global Balanced Salt Solutions Market Application Segments:Biopharmaceuticalstherapeutics, Stem Cell Technology, Drug Screening & Development, Genetic Engineering, Cancer Research, Others

Reason to access this report:1) This report segments the Balanced Salt Solutions market comprehensively and provides the closest market size estimation for major industries across various regions.2) The report would help stakeholders understand the pulse of the market and provide them with information on drivers, restraints, challenges, and opportunities for the market.3) This report would help stakeholders understand their competitors better and gain more insights to improve their position in the business.4) The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, and recent developments in both historic and present contexts.5) The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.6) rmr wrldwd Balanced Salt Solutions rkt mnufturng mn, t f, lrf nd nlz th rdut l munt, vlu nd mrkt hr, mrkt rvlr lnd, W nl nd dvlmnt ln nt mng r.7) The competitive landscape section includes competitor ecosystem, product launches and developments, partnerships, fund raising, and acquisitions.

Some of the key questions answered in this report:What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Configure, Price, Quote (CPQ) Software market?What was the size of the emerging Configure, Price, Quote (CPQ) Software market by value in 2020?What will be the size of the emerging Configure, Price, Quote (CPQ) Software market in 2026?Which region is expected to hold the highest market share in the Configure, Price, Quote (CPQ) Software market?What trends, challenges and barriers will impact the development and sizing of the Global Configure, Price, Quote (CPQ) Software market?

Table of ContentsReport Overview:It includes research scope, major manufacturers covered, market segments by type, Balanced Salt Solutions market segments by application, study objectives, and years considered.Global Growth Trends:Industry trends, the growth rate of key producers, and production analysis.Balanced Salt Solutions Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.Market Size by Type:It includes analysis of price, production value market share, and production market share by type.Market Size by Application:This section includes Balanced Salt Solutions market consumption analysis by application.Profiles of Manufacturers:Here, leading players of the global Balanced Salt Solutions market are studied based on sales area, key products, gross margin, revenue, price, and production.Balanced Salt Solutions Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Balanced Salt Solutions market value chain, and sales channel analysis.Market Forecast Production Side:In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Read Detailed Index Report @https://www.industryandresearch.com/report/Global-Balanced-Salt-Solutions-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201676

The report analysis their Sales data, Main Products, Services, and their profiles as well. Then, the report explores the international major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company. Through the statistical analysis, the report depicts the global market of Balanced Salt Solutions industry including capacity, production, production value, cost/profit, supply/demand, and Southeast Asia import/export. The research experts use exclusive mixture of primary and secondary research, different analytics, and industry research to give a holistic view of the Balanced Salt Solutions market and business ecosystem. The Global Balanced Salt Solutions market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2025. On the basis of historical data, Balanced Salt Solutions market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Balanced Salt Solutions industry is likely to appear as a commendable platform for emerging Balanced Salt Solutions market investors.

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the Balanced Salt Solutions markets.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@industryandresearch.com

See the article here:
Balanced Salt Solutions Industry Key Drivers, Business Insights And Forecast 2026 |Thermo Fisher Scientific, Lonza Group, Dickinson, EMD Millipore -...

Read More...

Exosome Therapeutic Market : SWOT Analysis of Top Key Player & Forecasts || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim…

Wednesday, September 9th, 2020

A persuasive Exosome Therapeutic Market report can be explored more specifically in terms of breakdown of data by manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks and entry barriers, sales channels & distributors. The data and information have been derived from the reliable sources and include websites, annual reports of the companies, journals, and mergers which have been again checked & validated by the market experts. The estimations of CAGR values are also provided in this wide ranging Exosome Therapeutic Market report which helps businesses in deciding upon the investment value over the time period.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

This Exosome Therapeutic Market report takes into account the conception of business goals and requirements to bridge the gap by delivering the most proper and suitable solutions. The competitive analysis is also performed in this report which covers strategic profiling of key market players, their core competencies & competitive landscape of the market which aids businesses characterize their individual strategies. In this market document, market drivers and market restraints are studied carefully along with the analysis of market structure. To provide an absolute overview of the Healthcare industry, Exosome Therapeutic Market analysis report covers various aspects of market analysis, product definition, market segmentation, key developments & the existing vendor landscape.

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Continued here:
Exosome Therapeutic Market : SWOT Analysis of Top Key Player & Forecasts || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim...

Read More...

Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United…

Wednesday, September 9th, 2020

DBMR has added a new report titledExosome Therapeutic Marketwith data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Exosome Therapeutic Market report is quite useful to find out the general market conditions and tendencies. It also estimates the probable market for a new product to be launched in the market. This also Report has compiled to provide various market aspects such as size, share, trends, dynamics, growth, sales, and industry analysis. The competitive analysis taken place in this Exosome Therapeutic Market report include strategic profiling of key market players, their core competencies, their strong and weak points, and competitive landscape of the market which supports businesses illustrate their individual strategies.

The Exosome Therapeutic Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Exosome Therapeutic Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Table of Contents:

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ [emailprotected]

Continue reading here:
Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United...

Read More...

COVID-19: Investigations in the Time of Coronavirus: Conducting FCPA Investigations during the Pandemic | Latin America – ICLG.com

Wednesday, August 12th, 2020

Latin America has been especially hard hit in recent months by the ongoing COVID-19 pandemic, as describe...

Latin America has been especially hard hit in recent months by the ongoing COVID-19 pandemic, as described in WilmerHales recent client alerthere. The resulting travel restrictions, physical safety precautions and public health concerns have created uncertainty for many companies confronting the need to conduct cross-border Foreign Corrupt Practices Act (FCPA) investigations in the region, where some countries are currently difficultor impossibleto access.[1]

Despite these challenges, effective internal investigations remain central to a robust FCPA compliance program, as underscored by the recently released FCPA2020 Resource Guide, summarized by WilmerHalehere. The Department of Justice (DOJ) has announced that it does not expect any slowdown in its FCPA enforcement actions during the pandemic.[2]Moreover, the goals of an internal investigation go beyond satisfying the requirements of government authorities. Conducting a thorough, reliable and effective FCPA investigation is in the best business interests of the company itself.

With this difficult environment in mind, this client alert sets out 10 key tips for conducting effective Latin America-focused FCPA investigations under pandemic conditions.

The first step in any internal investigation is important: frame the investigation. Ask the following questions, which can be especially important and complex during the pandemic:[3]

In any Latin American FCPA investigation, having a well-organized team in place is criticaleven more so during the current crisis. While the pandemic restricts travel, an investigation may rely even more heavily on local resources to stand up, carry out and manage the investigation.[4]

A combination of local and international expertise is essential. Be sure to consider the language skills of these team members and to structure any engagement so that their work enjoys applicable attorney-client privilege and/or work product privilege protections. The team should include:

A crucial consideration for assembling a team is understanding how legal privilege will apply. Failing to understand how privilege appliesor doesntin the country where the investigation is taking place can be a major and potentially fatal pitfall. Because many Latin American countries are civil law jurisdictions, their legal privilege protections operate in a manner fundamentally different from those familiar to US lawyers.[5]

For example, only in fall 2019 did Mexicos antitrust authority, the Federal Economic Competition Commission (COFECE, as abbreviated in Spanish), issue guidelines for recognizing attorney-client communication protections in connection with antitrust investigations.[6]Although Mexican law does generally prohibit the disclosure of client information, it does not include broad legal protection from government seizure. This risks sensitive disclosure to government authorities if not handled correctly. Recent case law suggests that these protections may be expanding, but the current legal landscape presents more questions than answers.[7]

Companies should be vigilant in maintaining and protecting privileged material during the course of a Latin America FCPA investigation. This may prove even more important during the pandemic, when coordinating is more likely to be done via email, text and other written meansmeans that government authorities may try to collect and over which companies may not have as much control as in non-pandemic conditions.

Even prior to the pandemic, preserving, archiving and collecting local documents and evidence for investigations in Latin America could prove challenging. Today, in the midst of COVID-19, those challenges have multiplied. Working swiftly and coordinating with the on-the-ground team will be critically important.

Prompt document preservation is the most important first step to ensure a complete investigation. Of course, relying on individuals themselves for preservation and collection while working remotely raises its own issues. When planning out the document preservation and collection process, consider how to stage processes and requests to minimize the possibility of spoliation. A truly bad actor may be willing to destroy evidence at the first sign of an investigation, so to the extent practical, IT should take steps to preserve evidence (such as by remote back up and capture of data) before preservation notices are sent.

Once those key preservation steps have been taken, another important step is sending a preservation notice to individuals who are likely to have relevant evidence. The preservation notice directs these individuals not to delete or destroy material relevant to the investigation.[8]In Latin America, even in companies where employees are expected to have a working knowledge of English, providing translations of this noticein Spanish, Portuguese and/or any other relevant languageswill be critical to ensuring compliance. In addition, employees who receive a preservation notice should be required to acknowledge receipt via email or other written means, and IT experts should track this acknowledgment information.[9]

The pandemic will likely also make traditional in-person collection efforts difficult if not impossible to complete, so creativity will be required. Obviously, where employees cell phones or laptops can be imaged remotely, such imaging is a key first step. In addition, identifying and collecting text messages, chats and conversations through applications such as WhatsApp (widely used for business in Latin America) is essential.[10]You may also consider collecting from personal accounts or personal devices, especially if individuals indicate that they used personal accounts for business-related communications and data storagewhich is likely happening more often with people working more from home. But when doing so, pay particular attention to the limits local privacy law and regulation may place on those efforts, as discussed next.

The process of preserving and collecting relevant data and documents is made more complex by Latin Americas patchwork of data privacy protections, which can complicate even the most straightforward FCPA investigation. This is especially true if an investigation might attract the interest of enforcement authorities in the United States or Europe. Add to this the specific challenges presented by the pandemic, and the risks can seem dizzying. Local counsel or US counsel with links to trusted local practitioners will be invaluable in navigating Latin Americas complex and ever-changing data privacy regimes.

Many Latin American countries have been heavily influenced by the European Unions General Data Protection Regulation. But countries in the region also have adopted a special emphasis on consent for processing data and for legitimizing transfers to inadequate countries (though it is rarely clear which outside countries are deemed adequate).[11]Each country also presents unique data protection rules and investigation challenges, which require country-specific legal analysis. For more discussion on privacy laws in Latin America, see WilmerHales detailed analysishere.

Not surprisingly, the pandemic itself now shapes and tests the regions maintenance of these privacy rules. In Brazil and Panama, for example, the implementation of recently enacted privacy laws will likely be postponed in response to the pandemic.[12]On the other hand, COVID-19 and the response to it have complicated some of the commonly used approaches to comply with foreign data privacy laws. In some cases, investigation teams have deployed US counsel to review data within the jurisdiction; that is difficult now, if not impossible, in many jurisdictions due to travel restrictions.

With this complicated and ever-changing set of data privacy protections across Latin Americamany of which are not intuitive to counsel trained in the United States, Europe or elsewherecompanies conducting FCPA investigations in Latin America should engage local experts to ensure that an investigation does not run afoul of local data privacy laws.

In addition, local labor and employment law may impact when, how and whether employee interviews may take place in an FCPA investigation as well as what the scope of permissible employee discipline may be. A discussion of employment law across Latin America is beyond the scope of this alert. The complexity of local employment law, like privacy law, underscores the importance of considering at the outset of an FCPA investigation whether and how to engage experienced local counsel in the jurisdiction at issue.[13]

As WilmerHale described in its2019 FCPA Year in Review, local enforcement authorities in Latin America have continued recently to investigate alleged corruption within their borderswith or without US authorities cooperation.

For example, Brazils President Jair Bolsonaro initiated his administration in January 2019 with a promise to stamp out corruption in Brazil. President Bolsonaro has introduced broad anti-corruption legislation[14]and Brazilian prosecutors have been active over the past few years in tackling deep-rooted corruption in the country. However, the pandemicand the Bolsonaro administrations own corruption scandalspresent fundamental challenges to these goals, including the Brazilian governments diversion of resources that had been dedicated to investigating and prosecuting COVID-19-related corruption.[15]

In Mexico, President Andrs Manuel Lpez Obrador also campaigned on an anti-corruption platform and took actions at the outset of his administration to combat graft. For example, his administration has gone after the countrys national oil company, Pemex, including charging and even arresting former Pemex executives living abroad.[16]In 2019, President Obrador appointed the countrys first chief anticorruption prosecutor, Luz Mijangos Borja, who was reported to have initiated 680 investigative cases in the first eight months of her term.[17]

Given this and similar recent investigation activity,[18]local enforcement interests have always been an important consideration in FCPA investigations. But during the pandemic, local authorities enjoy greater access to documents and individuals on the ground than do US officials. The importance of expecting and planning for potential local investigations is only heightened as a result.

Communication with relevant outside stakeholders in an FCPA investigation, including, where relevant, enforcement authorities and external auditors, has always been critically important.

The pandemic has only underscored this need for communicationDOJ and Securities and Exchange Commission (SEC) officials have recently highlighted the importance of communicating COVID-19 challenges to enforcement authorities, and they have signaled that these agencies will work with companies to address investigatory issues presented by the pandemic. For example, in April, officials from the DOJ and SEC FCPA units explained that they are trying very hard to be sensitive to the realities of what everybody is dealing with.[19]A few weeks thereafter, in mid-May, DOJ and SEC officials shared that their foreign bribery units were experiencing pandemic-related challenges but were in no way hitting the pause button on their investigations.[20]

Similar considerations also apply to communicating with external auditors. In certain instances, a company may be required to inform its regular outside auditor of an FCPA investigation.[21]In those cases, pandemic-related challenges that affect the inquirys timing, scope and action plan should be communicated to external auditors sooner rather than later.

Although the pandemic presents challenges to Latin America FCPA investigations for companies and regulators alike, it has also presented opportunities to take advantage of new technologies and creative strategies. For example, firms might cut significant costs by standing up remote document review platforms via remote secure workspacesof course, ensuring compliance with local privacy laws.[22]For further discussion of such technology and strategies in the investigations and strategic response context, see WilmerHales analysishere. (WilmerHale also releases CLE credit webinars about cutting-edge investigation strategies during COVID-19, ashere, so please feel free to subscribe to the latest news and events from the firm.)

In the current environment, conducting interviews virtually where possible under local law and investigation circumstances has become a common approach.[23]Video interviews, of course, pose their own challenges and limitations. It is important to be realistic about how long participants can be engaged during a videoconference;[24]it may be better to break interviews into two half-day sessions rather than one full day. Finally, in the interest of maintaining the confidentiality of the investigation, counsel should attempt to avoid sending documents to the intervieweeparticularly one who is not employed by the client or its subsidiarybut rather should try to share documents on screen during the interview, in real time.

When relying on new technologies, hope for the best but plan for the worst. For example, if you are conducting a videoconference, have a backup telephone line. If conducting remote document review, make sure to build in time for technical difficulties and system shutdowns.

Finally, the most important tip for conducting an FCPA investigation in Latin America during the pandemic:be flexible. Companies, individuals and regulators are all working to continue their lives and livelihoods during this global health emergency. Even the most seasoned investigators should be prepared for both the challenges and the opportunities presented by the pandemic, as outlined in each of the tips above.

WilmerHale, too, remains abreast of the latest developments in FCPA enforcement, Latin America COVID-19 response (for example, see WilmerHales latest client alert onCOVID-19 response in Latin America) and other legal issues around the globe. We are available to provide timely guidance for our clients and partners.

WilmerHale has strong relationships with a wide range of local consultants and local counsel throughout Latin America. In certain countries, we have connections with multiple firms that might be considered collaborative partners, depending on the nature of the matter. The firm also taps its alumni network where useful in pursuit of our clients legal and business objectives. These resourcesemployed in concert with WilmerHales FCPA investigation expertisehave helped countless firms navigate complicated and high-stakes issues in cross-border investigation and litigation, including some of the most common complications discussed in this alert.

[1] Since March 31, 2020, the US State Department has issued a global level four do not travel health advisory, encouraging US citizens to avoid all international travel due to the global impact of COVID-19. Furthermore, some Latin American countries, such asArgentina,Bolivia,Chile,Colombia,Costa Rica,El Salvador,Guatemala,PanamaandParaguayhave effectively closed their borders to non-citizens and non-residents.Ecuadoris imposing a mandatory 14-day preventative quarantine on all non-citizens and non-residents in government-approved temporary housing or hotels. Some countries, such asBrazil,Mexicoand theDominican Republic, still have at least somewhat open borders. However, Mexico has announced that it allows only essential travel of non-citizens and non-residents from the United States, and some travelers may be asked to provide an employer letter certifying the essential nature of their business at hotels.Seehttps://mx.usembassy.gov/travel-restrictions-fact-sheet/.

[2] At a virtual FCPA conference on July 14, DOJ Criminal Division Chief Brian Rabbit stated that he expects to see a number of FCPA settlements this year: 2020 has obviously been challenging in a number of different ways, but we have been able to move forward with a number of key prosecutions and resolve a number of cases in 2020, including the Novartis case. I expect to see more of those in the coming months additional FCPA resolutions despite the pandemic, so that obviously remains a priority.https://globalinvestigationsreview.com/article/jac/1228948/acting-criminal-division-chief-expects-more-fcpa-resolutions-in-coming-months.

[3]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[4]https://www.wilmerhale.com/en/insights/publications/2016-11-22-united-states-handling-internal-investigations;https://www.wilmerhale.com/en/insights/publications/20171220-beginning-an-internal-investigation-the-uk-perspective.

[5]https://www.americanbar.org/groups/business_law/publications/blt/2016/07/12_borrasso/.

[6]https://www.cofece.mx/wp-content/uploads/2019/09/DOF-30septiembre2019-01.pdf;https://www.justice.gov/opa/pr/antitrust-division-applauds-recognition-attorney-client-privilege-mexicos-competition-agency.

[7]https://globalcompetitionreview.com/article/1209247/mexico-recognises-legal-privilege-in-antitrust-probes

[8]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[9]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[10]https://www.wilmerhale.com/en/insights/publications/united-states-handling-internal-investigations.

[11]https://www.wilmerhale.com/en/insights/media/recording---wilmerhale-webinar-emerging-privacy-and-cybersecurity-laws-in-latin-america-and-asia.Unless otherwise indicated, all references in this section come from this WilmerHale webinar.

[12] For example, last year, Panama enacted a data protection law that was scheduled to enter into force in March 2021; only time will tell whether the pandemic slows the implementation or enforcement of this regulation.Seehttps://www.lexology.com/library/detail.aspx?g=58c7fd6b-d468-40fb-b330-83c4d9387585. And in Brazil, lawmakers recently voted to postpone the deadline for compliance with the General Data Protection Law from August 2020 to January 2021, citing concerns about the economic impacts of the pandemic (seehttps://www.wilsoncenter.org/blog-post/impact-postponing-brazils-data-protection-law;https://economia.estadao.com.br/noticias/geral,senado-aprova-projeto-que-suspende-prazos-contratuais-ate-outubro-aluguel-residencial-fica-de-fora,70003259159).

[13] See, e.g.,https://globalinvestigationsreview.com/chapter/1179068/beginning-an-internal-investigation-the-uk-perspective, 5.3.2.

[14]https://www.wilmerhale.com/en/insights/client-alerts/20200228-latin-america-anti-bribery-year-in-review-2019-developments-and-predictions-for-2020

[15]https://www.cnn.com/2020/07/08/americas/brazil-coronavirus-corruption-intl/index.html;https://www.ft.com/content/94c87005-7eb1-47c4-9698-5afb2b12ab54;https://riotimesonline.com/brazil-news/brazil/politics-brazil/investigations-on-covid-19-related-corruption-amount-to-r1-07-billion/.

[16]https://www.wilmerhale.com/en/insights/client-alerts/20200228-latin-america-anti-bribery-year-in-review-2019-developments-and-predictions-for-2020

[17]https://fcpablog.com/2019/12/18/new-corruption-prosecutor-opens-680-investigations/.

[18] Other Latin American enforcement authorities that have shown recent interest in dedicating significant resources to corruption investigations include Ecuador, in the case of PetroEcuador, for example, and Venezuela, in the case of PDVSA, for example.WilmerHale, Foreign Corrupt Practices Act Alert: Global Anti-Bribery Year-in-Review: 2018 Developments and Predictions for 2019(Jan. 17. 2019),https://www.wilmerhale.com/en/insights/client-alerts/20190117-global-anti-bribery-year-in-review-2018-developments-and-predictions-for-2019.

[19]https://globalinvestigationsreview.com/article/jac/1226073/fcpa-officials-urge-companies-to-communicate-pandemic-related-difficulties-quickly.

[20]https://globalinvestigationsreview.com/article/jac/1226760/sec-enforcement-chief-discusses-coronavirus-challenges;https://globalinvestigationsreview.com/article/jac/1227005/were-not-hitting-the-pause-button--says-sec-foreign-bribery-chief.

[21]https://www.sec.gov/spotlight/fcpa/fcpa-resource-guide.pdf.

[22]https://www.wilmerhale.com/en/insights/client-alerts/20200409-government-investigations-and-covid-19-remain-engaged-and-prepare-for-a-post-crisis-response.

[23]https://www.wilmerhale.com/en/insights/client-alerts/20200409-government-investigations-and-covid-19-remain-engaged-and-prepare-for-a-post-crisis-response.

[24]https://www.wsj.com/articles/why-does-zoom-exhaust-you-science-has-an-answer-11590600269.

This article was first published here.

Read this article:
COVID-19: Investigations in the Time of Coronavirus: Conducting FCPA Investigations during the Pandemic | Latin America - ICLG.com

Read More...

Global Cell Proliferation Kit Market 2020 Divided By Product Type And Application Segment: Biological Industries, Thermo Fisher Scientific,…

Wednesday, July 8th, 2020

EON Market Research has published an innovative statistics of the market titled as Cell Proliferation Kit Market Size Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, Cell Proliferation Kit Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Future Growth Potential Forecasts 2025. In the next few years, analyzes the current market size and development in this sector.

Following are the Topmost key players covered in this Cell Proliferation Kit Market research report:

Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich (Merck), BD Biosciences, GE, PerkinElmer, Millipoore (Merck), Bio-Rad, Biotium

Request a Sample Report of Cell Proliferation Kit Market at:https://www.eonmarketresearch.com/sample/68568

The report offers a critical supposition identifying with the Global Cell Proliferation Kit Market by examining of its division. The divisions were assessed in terms of current and also future patterns. The Study of geographical segmentation incorporates the estimated and present necessities from these areas. In addition, the study provides a need related to different end-use segments and separate products in a large part of the geographic segments. of the Global Cell Proliferation Kit Market. The report additionally examinations the Cell Proliferation Kit advertise as far as volume and income.

Divided by product type, with production, revenue, price, Cell Proliferation Kit market share and growth rate of each type, can be Split into

Colorimetric Detection MethodFluorescent Detection MethodOther

Divided by application, this report focuses on the consumption, market share and growth rate of Cell Proliferation Kit in each application and can be Split into two parts.

ClinicalIndustrial and Applied ScienceStem Cell Research

Geographic Market Analyzed in:-

Cell Proliferation Kit industries in Europe (Netherlands, Germany, Sweden,Switzerland, San Marino, Ireland, Norway, Luxembourg etc)Cell Proliferation Kit Markets in North America (Panama, Mexico, Barbados,United States, Canada, Puerto Rico,Trinidad and Tobago etc)In Asia-Pacific(United Arab Emirates, Qatar,China, India, Hong Kong, Korea, Israel, Australia, Singapore, Japan, Kuwait, Brunei, etc)Middle East and Africa (Egypt, Algeria,Nigeria, South Africa, Angola, Saudi Arabia, Bahrain, Oman, Turkey, Lebanon etc)Cell Proliferation Kit Market in South America (Belize, Costa Rica,Panama, Guatemala,El Salvador, Honduras, Nicaragua) and the Rest of the World.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/68568

The study analyzes the following key business aspects:

1. Industry overview: Definition, a brief introduction of Major Applications.

2. Competitors Review of Cell Proliferation Kit Market: The competitive landscape scenario seen among top Cell Proliferation Kit players,revenue, sales, business tactics and forecast Cell Proliferation Kit industry situations are presented in this report.

3. Production Market Analysis: Price, revenues, cost, and gross margin analysis.

4. Sales Market analysis: by volume, sales revenue and by major manufacturers Success in the past.

5. Supply and Demand Review of Cell Proliferation Kit Market: Along with sales margin, the supply and demand were seen in major regions, Traders, among key players and for every Cell Proliferation Kit product type are presented in this report. Import/export scenario is also reflected in Cell Proliferation Kit report.

6. Other key reviews of Cell Proliferation Kit Market: Apart from the above information, the company website, number of employees, contact details of major Cell Proliferation Kit players, potential consumers and suppliers are presented in this report. The strengths, opportunities, Cell Proliferation Kit market driving forces and market constraints are also addressed in this study.

Do Inquiry Before Purchasing Report Here: https://www.eonmarketresearch.com/enquiry/68568

About us:

EON Market Research is a market research-based company that empowers data-driven companies. We provide accurate and well-informed market research reports, Real-Time with Real Application. Good research methodology proves to be effective and concise knowledge that uses complex decisions from day-to-day to day-to-day life to help us manage vision, intention and well-armed strategies. At EON Market Research, we are constantly striving for excellence in the techniques and consistency of research in our studies.

*** Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Read the original:
Global Cell Proliferation Kit Market 2020 Divided By Product Type And Application Segment: Biological Industries, Thermo Fisher Scientific,...

Read More...

Stem Cell Therapy in San Jose, Costa Rica – Stemedix …

Friday, June 19th, 2020

Escaz is situated along the slopes of Cerro Escaz and is considered one of the most trendy and upscale suburbs of the San Jos metropolitan area. The city is located 7.5 miles (12 km) from San Jos and is a great place to enjoy the same amenities of the larger, busier city, but with a more relaxing feel. In Escaz, you can enjoy the unique atmosphere of Costa Rica with all the modern amenities you could want at your fingertips.

In town, there is a wide variety of little shops, boutiques, cafs, and restaurants. Some popular US chain restaurants are also available dining options. This is also home to the countrys largest shopping center, Multiplaza, a two-story mall located within minutes of the Stemedix offered hotels. This is where you can check out the latest fashion, watch a movie, or just walk around the enormous commercial center. Explore the culture of Costa Rica with nearby museums, National Theater, and architectural and historical landmarks. More adventure awaits with available tours, mountain view dining, and waterfall excursions.

See the article here:
Stem Cell Therapy in San Jose, Costa Rica - Stemedix ...

Read More...

Exosome Therapeutic Market 2020 Major Growing Factors and Top Driving Force with Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE…

Friday, June 19th, 2020

This Exosome Therapeutic Market business research report gives analysis and data according to categories such as market segments, regions, types, technology, end-user, applications and so on. The report offers the current industry data and upcoming trends of the industry, allowing the recognition of the products and end users boosting revenue growth and profitability. Moreover, this Exosome Therapeutic Market analysis document is structured with different graphical representations like graphs, charts, figures and diagrams with the specific arrangement of vital outlines, strategic diagrams, and illustrative figures based on reliable information to depict a correct picture of value judgement and income graphs.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

More:
Exosome Therapeutic Market 2020 Major Growing Factors and Top Driving Force with Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE...

Read More...

Stem Cells Green Healthcare Costa Rica

Sunday, May 24th, 2020

Language

Please select oneArabicEnglishEnglish (Canada)English (United States)SpanishSpanish (Colombia)AlbanianAlbanian (Albania)Arabic (Algeria)Arabic (Bahrain)Arabic (Egypt)Arabic (Iraq)Arabic (Jordan)Arabic (Kuwait)Arabic (Lebanon)Arabic (Libya)Arabic (Morocco)Arabic (Oman)Arabic (Qatar)Arabic (Saudi Arabia)Arabic (Sudan)Arabic (Syria)Arabic (Tunisia)Arabic (United Arab Emirates)Arabic (Yemen)BelarusianBelarusian (Belarus)BulgarianBulgarian (Bulgaria)CatalanCatalan (Spain)ChineseChinese (China)Chinese (Hong Kong)Chinese (Singapore)Chinese (Taiwan)CroatianCroatian (Croatia)CzechCzech (Czech Republic)DanishDanish (Denmark)DutchDutch (Belgium)Dutch (Netherlands)English (Australia)English (India)English (Ireland)English (Malta)English (New Zealand)English (Philippines)English (Singapore)English (South Africa)English (United Kingdom)EstonianEstonian (Estonia)FinnishFinnish (Finland)FrenchFrench (Belgium)French (Canada)French (France)French (Luxembourg)French (Switzerland)GermanGerman (Austria)German (Germany)German (Greece)German (Luxembourg)German (Switzerland)GreekGreek (Cyprus)Greek (Greece)HebrewHebrew (Israel)HindiHindi (India)HungarianHungarian (Hungary)IcelandicIcelandic (Iceland)IndonesianIndonesian (Indonesia)IrishIrish (Ireland)ItalianItalian (Italy)Italian (Switzerland)JapaneseJapanese (Japan)KoreanKorean (South Korea)LatvianLatvian (Latvia)LithuanianLithuanian (Lithuania)MacedonianMacedonian (Macedonia)MalayMalay (Malaysia)MalteseMaltese (Malta)NorwegianNorwegian (Norway)Norwegian (Norway, Nynorsk)PolishPolish (Poland)PortuguesePortuguese (Brazil)Portuguese (Portugal)RomanianRomanian (Romania)RussianRussian (Russia)SerbianSerbian (Bosnia and Herzegovina)Serbian (Latin)Serbian (Latin, Bosnia and Herzegovina)Serbian (Latin, Montenegro)Serbian (Latin, Serbia)Serbian (Montenegro)Serbian (Serbia and Montenegro)Serbian (Serbia)SlovakSlovak (Slovakia)SlovenianSlovenian (Slovenia)Spanish (Argentina)Spanish (Bolivia)Spanish (Chile)Spanish (Costa Rica)Spanish (Cuba)Spanish (Dominican Republic)Spanish (Ecuador)Spanish (El Salvador)Spanish (Guatemala)Spanish (Honduras)Spanish (Mexico)Spanish (Nicaragua)Spanish (Panama)Spanish (Paraguay)Spanish (Peru)Spanish (Puerto Rico)Spanish (Spain)Spanish (United States)Spanish (Uruguay)Spanish (Venezuela)SwedishSwedish (Sweden)ThaiThai (Thailand)TurkishTurkish (Turkey)UkrainianUkrainian (Ukraine)VietnameseVietnamese (Vietnam)

Please select oneRotator CuffSpinal Cord InjurySC Therapy DiabetesPeripheral NeuropathyProximal NeuropathyRANeuropathy and DiabeticOAParkinson's DiseaseSLEMSMyocardial InfartionDegenerative Disc DiseaseErectile DysfunctionFocal NeuropathyCOPDCranial NeuropathyCritical Limb IschemiaAnti-agingDANCardiovascular DiseaseAlzheimer's DiseaseALSASD

Go here to see the original:
Stem Cells Green Healthcare Costa Rica

Read More...

Stem Cell Treatment for COPD in Costa Rica – MyMediTravel

Sunday, May 24th, 2020

Stem Cell Treatment for COPD in and around Costa Rica

About Costa Rica

Costa Rica is a great place to be adventurous or for those who just want to relax and unwind. With more than 1,000 miles of coastline, the country is home to some of the world's most beautiful beaches(If you are looking for lots of sun, avoid the rainy season, between April and November). It is one of the top surfing destinations in the world, the water is warm year-round.

With its own delicious national cuisine, the country is also a huge grower of coffee, bananas and chocolate. If you visit Quepos, be sure to take a tour at Villa Vanilla farms to see how they make chocolate as well as vanilla, pepper, cinnamon and more. It is known as the happiest country on Earth. A common saying among locals is pura vida, which means pure life. Everywhere you go in Costa Rica, you will be welcomed with a smile by the locals. About 25% of the Costa Rica is made up of protected national parks and rainforests which hold 5% of the world's biodiversity and the country has very rich and fertile soil which helps make it so lush and full of life. The volcanoes and surrounding areas are also popular areas for hiking, camping and mountain biking.

Costa Ricas has two JCI-accredited hospitals and numerous smaller, private AAAASF-accredited and AAAHC-accredited clinics offering a wide range of medical services, including orthopedics, cardiology, cosmetic surgery, and bariatrics. Idyllic scenery and unique recovery lodges which has made Costa Rica a prime destination for the medical tourists,many of which travel for Stem Cell Treatment for COPD procedures.

Read this article:
Stem Cell Treatment for COPD in Costa Rica - MyMediTravel

Read More...

Boris is back, and we need him to end the coronavirus crisis and heal the NHS – Telegraph.co.uk

Tuesday, May 5th, 2020

Matt Hancock has said there are early signs showing that the antiviral drug hydroxychloroquine may be a very effective treatment, implying the government is acquiring significant stocks of it. This is the correct approach. Trustworthy research has found it disrupts the endocytosis process ruffling of cell membrane to ingest particles and nutrients from its surrounding environment meaning it blocks the entry of Covid-19.

In the same way, hydroxychloroquine can also starve cancer given cancer cells grab extracellular nutrients to feed themselves. Looking forward, we need to modernise our cancer care in the UK. We sadly have some of the worst stats for cancer recovery in Europe. Our cancer survival rates are not just worse than America, Scandinavia, Canada, or Australia, for some cancers, they are even worse than Brazil or Costa Rica.

Conventional NHS therapy must move with the science, this includes repurposing existing drugs, traditionally used for other conditions, which are proving to disrupt the metabolic pathways of cancer cells. There is a huge untapped medicine cabinet of generic drugs and herbs that could help treat cancer, and many other conditions such as motor neurone disease and schizophrenia. Despite facing a record-breaking 17 billion annual drugs bill, the NHS still retains an outdated, rigid attitude to innovation. This drugs bill is rising around 8% a year, as the NHS struggles in negotiations with Big Pharma to keep costs down.

In the US, the costs of cancer care have also surged by 40% in the past decade. There is existing evidence suggesting that, together, these repurposed drugs disrupt the metabolic pathways of cancer cells to slow down or prevent their reproduction. They are among several cheap drugs with proven anti-cancer properties that are not available to NHS cancer patients. Many thousands of published scientific studies already show they can disrupt tumour growth by reducing cancer cell nutrition, and the Medical Research Council (MRC) is running clinical trials to begin to collect more data on the benefits of these repurposed drugs. But the results are at least a decade away, and the dose of aspirin being used in this MRC trial is not one that is commercially available anyway.

To improve cancer care in the NHS, we need a parallel support system for people that links in with NHS treatment, but allows them to access the best of other science-based treatments, of personalised medicine such as circulating tumour DNA analysis and cancer stem-cell treatment with integrated oncology. We also must find a mechanism and a structure for the regulators to allow out-of-patent drugs to be used again. Lets learn from best cases around the world.

We rightly cherish our NHS, even more so now than we ever did. Our carers deserve a new settlement once the pressure is lifted, as do other key workers like bin collectors, delivery drivers and cleaners. But in the long term we must ask ourselves seriously why, if the NHS is the envy of the world, in over 70 years no other country has copied it? We should take the opportunity to radically improve long-term healthcare in the UK and reform the NHS and social care system together once Covid passes.

The NHSs traditional levelling-down attitude that if something cant be offered to everyone then it shouldnt be offered at all is bad for innovation, bad for short-term care and bad for people who would otherwise benefit. Did you know around half of people get better after a cancer diagnosis? A shocking statistic mostly for people with one of the first three stages of cancer. I am aiming to join this 50% as I have Stage 4 breast cancer. Given just two years to live, Ive since made remarkable progress through one of these clinical trials using repurposed drugs.

Covid-19 has meant Ive ended up an accidental health tourist locked down in Thailand where Im watching from a distance whats happening in the UK. I am determined to play my part in increasing the survival figure by raising awareness of simple science-based things that help you to biohack your body, take control of your own health and beat the statistics. As my hero Marie Curie said: Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.

Katharine Harborne is a chartered environmental scientist, artist and a former prospective parliamentary candidate for the Brexit Party, and former Conservative councillor in the London Borough of Richmond.

Read more:
Boris is back, and we need him to end the coronavirus crisis and heal the NHS - Telegraph.co.uk

Read More...

Meet the 5 female finalists for the 2020 M&T Bank John Travers Award – PennLive

Sunday, April 26th, 2020

For the 39th year, M&T Bank, in conjunction with PennLive and the Harrisburg Lions Club, has been honoring central Pa.s top student-athletes with the John Travers Award.

The 2020 finalists have all excelled as athletes, students, and voices in their communities. Today, we shine a spotlight on the 5 female finalists.

Winners will be announced next month along with the A.I. Garner Outstanding Coach Award winner. The Travers Award is named for the late executive sports editor of The Patriot-News.

Gabriella Recce, Central Dauphin

Gabriella Recce Central Dauphin track and field during media day on February 28, 2019.Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Varsity sports: Track and Field (4 letters), Indoor Track (3 letters), Golf (4 letters), Cheerleading (1 letter), Swimming (1 letter)

College choice: University of Virginia

Finalists voice: I chose to pursue engineering as my career, because engineers can change the way we live in the world. Whether eradicating cancer and other debilitating diseases, improving our health with stem cell therapies, cleaning the environment with sustainable approaches or creating novel transportation methods, engineers are trained to solve problems and generate new solutions. My passion for this career comes from my dedication to my academic journey, my learning as a multi-event athlete and the support and encouragement of my family.

Describe yourself in one word: Positive

Gabriella Recce of Central Dauphin competes in the girls 3A long jump during the District 3 Track & Field Championships at Shippensburg University on May 18, 2019.Joe Hermitt | jhermitt@pennlive.com

Accomplishments: Theres no question Recce was aligned for a terrific final season in track and field. Earning three PIAA medals in the pole vault, long jump and triple jump at last years PIAA Championship meet, Recce was poised to add a few more records to her already glowing career. Shes earned a dozen top finishes during Mid-Penn and District 3 competitions. Plus, she qualified and competed at the prestigious Penn Relays, New Balance Outdoor and Indoor National competitions along the way. Recce was coming off an outstanding Indoor season when the spring sports calendar was canceled due to the coronavirus pandemic. Reece, also an accomplished golfer, helped the Rams golf team win a District 3 title in 2017. Vice-President of CDs National Honors Society, Recce also served as Editor of the Key Club and volunteered with PAWS, LPGA Girls Golf of Harrisburg, the Four Diamonds Club and PanRam Field Day for special needs students. In addition, the senior won a national gold medal in scholastic art and writing (2016) and was part of Hershey Medical Centers PULSE Program.

Katie Sajer, Trinity

Katie Sajer (20) of Trinity girls basketball during Mid-Penn basketball media day on Nov. 14, 2019.Dan Gleiter | dgleiter@pennlive.com

Varsity sports: Volleyball (4 letters), Basketball (4 letters), Lacrosse (4 letters)

College choice: University of Notre Dame

Finalists voice: The ROTC program offers chances to earn skill sets and exposure otherwise unavailable to civilians. These skills will be necessary to ensure the lives and safety of my team. By using my athleticism in this regard, I will be able to give back to the country that has made me into the person I am today, and fight for the people who came before me. I will be able to make a larger impact through this use of my athleticism than anything I would be able to do on the athletic field or court.

Describe yourself in one word: Hard-working

Trinity's Katie Sajer drives past a Central Dauphin defender during Central Dauphins 55-42 win over Trinity in the Mid-Penn girls basketball championship, February 13, 2020.Vicki Vellios Briner | Special to PennLiveVicki Vellios Briner | Special to PennLive

Accomplishments: Among the most versatile athletes in the Mid-Penn Conference, Sajer captained a pair of Trinity sports programs and is a two-time All-State pick in volleyball. In fact, Sajer was a 2019 nominee for the Under Armour High School All-American volleyball team. Awarded a national four-year Army ROTC Scholarship at Notre Dame, Duke University, the University of Delaware and Bucknell University, Sajer opted to focus on physical, mental and leadership training in South Bend. Sajer has worked as marketing intern for Pennsylvania Wounded Warriors, developing a campaign that has raised approximately $145,000 to support servicemen and women in Pa. Sajer, a member of Trinitys French Foreign Language Honors Society, also served as a property manager in her family business, and worked as a school mentor and activities leader.

Gery Schnarrs, East Pennsboro

Gery Schnarrs of East Pennsboro field hockey during high school football media day on July 31, 2019.Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Track and Field (2 letters)

College choice: University of Virginia

Finalists voice: I would tell young athletes to stay at it. Obviously, you are going to face a lot of obstacles. You are going to think a lot of times that, maybe if you dont make a team, you should move on to something different? I think its important to stay at it and keep following what you want to do. I think thats how you succeed. If you want to do it, then I think thats where youre going to put most of your effort.

Describe yourself in one word: Determined

Gery Schnarrs, East Pennsboro M/D (Univ. of Virginia). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Accomplishments: Ever since the Virginia recruit broke onto the field hockey scene, scoring 10 goals with 12 assists as a freshman, Schnarrs has impacted the Mid-Penn Conference and beyond. A current member of USA Womens National Indoor Development team, Schnarrs capped her brilliant run with a spot on Max Field Hockeys HS All-American team. She holds East Pennsboro career mark with 198 points and earned multiple All-State appointments. The Panthers won four straight division titles, and four trips to states, with No. 37 digging in. A Scholar of Distinction on the National Field Hockey Coaches Association Academic team, Schnarrs has served as treasurer for three different school programs, including that National Honors Society. A Girl Scouts Gold Award winner through her Get in the Game initiative. Schnarrs also won a Silver Presidential Volunteer Service Award last year and coordinated multiple service drives like Purses for a Purpose for the homeless and a bedding rive for the Speranza Animal Shelter. Shes also volunteered with the Bethesda Mission Womens Shelter, Salvation Army and more.

Marlee Starliper, Northern

Northern's Marlee Starliper shows off her NC State gear Sunday after committing to the Wolfpack.

Varsity sports: Cross Country (4 letters), Track and Field (4 letters), Indoor Track (4 letters)

College choice: North Carolina State

Finalists voice: I aspire to run professionally after college with the hope of having a long career in which I can pursue qualifying for several Olympic teams. Another aspect of y athletic goals is to continue enjoying the sport, have fun discovering more of my capabilities, and be a positive impact within the running community and beyond.

Describe yourself in one word: Passionate

Northern's Marlee Starliper trails Greencastle's Taryn Parks in the AAA 1600 meter run during day 2 of the 2019 PIAA Track and Field Championships at Shippensburg University. May 25, 2019 Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Accomplishments: Starlipers resume is overflowing with state and national records, including three consecutive PIAA cross country titles. She was runner-up as a freshman. Pa.s Gatorade Cross County Player of the Year three times, Starliper also twice claimed Foot Locker Northeast regional titles and was runner-up at Foot Locker Nationals in the fall. She now holds the states all-time mark. On the track, Starliper is a four-time state champion and her mile (4:37) and 3k (9:07) standards rank No. 1 nationally. Invited to the Reykjavik Games in Iceland by the National Scholastic Athletic Foundation, Starliper finished third in the 800. Shes also competed for USATF in the Pan-American Games in Costa Rica, becoming a U20 national champion. An active member of the World Harvest Outreach Church in Chambersburg, Starliper has participated in Direct Call, a student-led Christian group at Northern, volunteered as a Special Olympics buddy and served a regular speaker to middle school cross country and tracks teams about nutrition. Recently, Starliper signed to write and illustrate a childrens book in Spanish.

Maddie Zimmer, Hershey

Maddie Zimmer, Hershey MF (Northwestern). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Lacrosse (3 letters)

College choice: Northwestern University

Finalists voice: This winter Ive actually been helping to coach at multiple field hockey clubs. I never thought I would like it, but I actually really like coaching the little girls. I didnt think I had the patience for it, but they improved so much and its so rewarding to see how excited they are. Thats how I was when I was their age. All I wanted to do was play field hockey and its so exciting to be a part of their journey. Its so rewarding and fun to watch.

Describe yourself in one word: Dedicated

Hershey's Maddie Zimmer brings the ball down field against Lower Dauphin in their high school field hockey game at Hershey. Sept. 11, 2019.Sean Simmers | ssimmers@pennlive.com

Accomplishments: As one of the nations top field hockey players in her class, Zimmer is a four-time All-State pick and high school All-American in her final two seasons. The midfielder also led the Trojans to the PIAA Class 3A title in 2018. She also earned US Lacrosse All-American honors as a junior. Continuing to rehab an ACL tear she suffered in November, Zimmer is planning to compete for the U21 U.S. National Field Hockey Team against Ireland in June. Her first cap came against Canada last summer. After Ireland will be the Junior Pan American Games in Chile, an official qualifier for the 21 Junior World Cup. Continuing to make an impact in her community, Zimmer has coached youth field hockey and lacrosse programs, donated her time to Purses full of Hope, raised funds for the Walk for Clean Water Organization and co-chaired the Herren Project, a non-profit that supports families with addiction and prevention of substance abuse.

2020 Travers Award female nominees

Follow Eric Epler on Twitter -- @threejacker

Thanks for visiting PennLive. Quality local journalism has never been more important. We need your support. Not a subscriber yet? Please consider supporting our work.

Originally posted here:
Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive

Read More...

FT Health: Coronavirus and the dangers of distraction – Financial Times

Friday, April 3rd, 2020

Welcome to FT Health, a monthly guide to the big issues at the intersection of global health and finance. Technology and investment are changing the face of healthcare while coronavirus is bringing an unprecedented focus on the worlds health systems. This newsletter delivers news, interviews, data and the best health journalism from across the web. Send us feedback at health@ft.com.

FT subscribers can sign up for the email versionhereand non- subscribershere.

Coronavirus: the dangers of distraction

Despite the intensifying globalisation of travel, trade and information in recent years, the current pandemic like those of the past shows that most countries only respond to an infection when it arrives on their doorstep. While health services are understandably focused on handling the surge of patients, the pandemic response highlights at least three risky distractions.

The first is the tension between short and long-term medical responses. While in most countries the current focus is on a lockdown of people to limit the spread of infection, along with urgently improving supplies of protection equipment, respirators and test kits for frontline workers, there is a need to start reflecting on an exit strategy.

As someresearchersare now arguing, efforts will need to escalate to differentiate between the most vulnerable and others who have survived infection and developed immunity, so they can return to essential work and support the economic recovery. Otherwise, the financial and associated health burden of poverty and isolation will end up being heavy. The models driving much of current policy do not considereconomic and ethicalfactors.

The second is the balance between coronavirus and existing burdensome illnesses. There are already reports of patients with cancer and other conditionsreceiving lower priority. High rates of childhood vaccination against preventable diseases will be difficult to sustain with prolonged social distancing. In lower-income countries, people with infections such as tuberculosis risk being turned away.

A final concern is the move away from international to domestic solidarity. Countries have closed borders, sought to restrict export of medical supplies and limited financial aid to their neighbours.But the neglect of international effortsto support or even focus on Africa and other poorer regions risks causing a disproportionatefinancial burden. In refugee camps, with scant medical support or even soap, thehuman tollcould be devastating.

To its credit, the Global Fund to Fight Aids, TB and Malaria has announcedup to 5 per centof its grants can be spent on Covid-19. More countries need to show similar solidarity to mitigate the damage to others or face the repercussions themselves.

Recommended links

Sir Alimuddin Zumla, Professor of Infectious Diseases and International Health, University College London, and joint guest editor of the International Journal of Infectious Diseasespecial issue on TB.

Following World TB Day, what progress and pitfalls do you see in tackling the disease?

We are moving forward, but very slowly. New drugs are being rolled out, with a simpler, shorter all-oral treatment, and Im optimistic well have a vaccine in 2-3 years time. We have seen political commitment fromthe presidents of Indonesia, Mozambique and the Philippines; the prime ministers of India and Pakistan andNigerias First Lady. I hope it is now backed by domestic fundingand their attention is not distracted by the Covid-19 pandemic.

How worried are you that coronavirus is proving a distraction?

Whole health services are now focused on Covid-19. Cancerpatients are having access problems. In Africa, we need to keep regular services afloat. Social distancing will make TB support challenging. Ministers are being politically pushed to respond because youve got to be seen to be doing something. But the best thing they can do is to make sure current services for TB, as well as HIV, malaria and maternal and child health, are not disturbedand Covid-19 is aligned to them.

Are there better ways to connect the medical response to TB and coronavirus?

There is a programme to expand TB GeneXpert diagnostics test equipment for coronavirus. Bothcause lethalrespiratory tract infections. People present with the same symptomsof cough, fever and breathlessness. We should take the opportunity to aligncommunitymessages and exploit synergiesin health services provisionincluding around diagnosis. With TB, as with Covid-19, we need to focus on the host, not the pathogen. For TB, that means tackling malnutrition, poverty, stress and poor living conditions.

Read more on the pandemics effect in our free-to-access collection of data and graphics. Heres an explainervideo on how we calculate the diseases trajectory.

Financing the crisis The IMF and World Bank are facing unprecedented demands from developing countries for help fighting coronavirus. The UN has called for a $2.5tn rescue package but the UN Security Council has been criticised for beingparalysed by theUS/China showdown over who was to blame for the disease spreading. Five world leaders wrote in the FT on the need for geopolitical turf wars to be set aside. (FT, Guardian, Foreign Policy, FT)

Chinas soft power After initial criticism of the way it handled the epidemic, China is keen to show itself as a responsible global power, sending doctors and masks overseas as its rates of domestic infections drop.

DRC: On life support The worlds biggest outbreak of measles in the Democratic Republic of Congo is one example of serious disease that has had little publicity in the shadow of Covid-19. A Unicef report highlights a health system struggling to cope with Ebola, cholera, malaria and measles amid ongoing armed conflict. (Al Jazeera, Unicef)

Safer surgery At least 42m people worldwide die within 30 days of surgery each year, and half of these deaths are in low- and middle-income countries. New surgical guidelines aim to save thousands of these lives, especially in the poorer countries that are disproportionately affected. (British Journal of Surgery)

Inequality in global healthThe new edition of theGlobal Health 50/50report says inequalities in power, privilege and priorities are undermining global health efforts. More than 80 per cent of those who lead the big international health organisations are from high-income countries and just five per cent are women from low- and middle-income countries. At the current rate of progress, gender parity in senior management will not be achieved until 2074. (Global Health 50/50)

Focus on...TBAs Sir Alimuddin Zumla notes in our interview above, progress on tackling diseases such as tuberculosis still the worlds top infectious killer could suffer from the worlds focus on Covid-19. The WHO says the preventive treatment agreed by world leaders in 2018 has fallen far short of its target. In that year alone, 10m people fell ill with TB and 1.5m lost their lives. TB also remains the top cause of death among people with HIV. Spending on TBin south-east Asia needs to be doubled from current levels to $2bn a year to make a serious attempt at ending the disease.As with coronavirus, young people remain key to prevention. (WHO, BMJ, The Conversation)

Hunt for coronavirus drugThe WHO and Unitaid, the UN-backed group funding global innovation, welcomed a proposal from Costa Rica for companies to pool intellectual property for all medical interventions, enabling governments or generic drugmakers to manufacture and sell at much lower prices. A therapeutics accelerator is giving $20m to speed drug trials.

Scientists are investigating three main types of drug: antiviralsto stop the virus from replicating; anti-inflammatories that treat the lungs after the immune system isoverwhelmed; and antibodies derived either from recovered Covid-19 patients or developed in labs, to be given to the seriously ill or as a temporary prophylactic for healthcare workers. (FT)

Vaccines and testsJohnson & Johnsonannounced a potential vaccine for Covid-19 that could be available early next year.The Coalition for Epidemic Preparedness Innovations is sponsoring severalvaccine projects, although Richard Hatchett, who heads this partnershipof governments, industry and charities, voiced fears about unequal access to treatment. He referredto the H1N1 flu in 2009, when the wealthiest countries secured contracts for deliveries of treatments that monopolised supplies. Tobaccocompanies are also getting involved. See too our guide to coronavirustesting.(FT, Devex)

Disease mappingAn innovative attempt at plugging health gaps in areas without detailed maps is blendingsatellite imagerywith machine-learning algorithms. (Devex)

Washing and sanitationIf theres one public health essential weve learned over the past few months, its the importance of washing your hands. But what if you dont have access to clean water? World Water Day this month was a time to remember that 40 per cent of the worlds people lack access to basic handwashing facilities at home, and 780m have no access to a quality water source. A UN reportsays climate change makes the goal of achieving access to safe drinking water and sanitation within ten years difficult. (Reliefweb, UN Water)

Tackling obesityChildhood obesity, recognised by the WHO as oneof the worlds most serious public health challenges,is linked to higher risk of anxiety, depression and premature death. People with obesity in childhood have a three-times higher risk of dying in early adulthood than their peers. An urban health foundation in London is taking a data-driven approach to tackling the problem. (PLoS Medicine, FT)

Combating diabetes Obesity is also a key driver of (Type-2) diabetes. An estimated four-fifths of diabetics, more than 336m people, live in lower- and middle-income countries, but there is no equivalent for the disease of the large-scale international support given to organisations such as the Global Fund to Fight Aids, TB and Malaria. Read the full FT report:Combating Diabetes

HIV hopes and fearsResearch has now been published on only the second HIV patientever to be cured of the disease, thanks to a stem cell transplant from donors with a HIV-resistant gene. Africanswith a disability are at much higher risk of HIV and less likely to receive treatment.Read how the discovery of HIV led to a transatlantic research war. (The Lancet HIV, Economist, PBS)

Fighting FGM UN targets to end female genital mutilation by 2030 are seriously off track, according to a coalition of global campaign groups. Unicef figures show FGM is inflicted on at least 200m women and girls in 31 countries, 27 of which are in Africa, and are likely to be grossly understated.(Equality Now)

Drug prices and UHCHigh medicine prices are a real threat to fledgling universal health coverage schemes. This study looks at the alternative ofvalue-basedtiered pricingwhich reflects both the ability of different countries to pay and the value that any medicine provides to local patients.

Children with cancer Some 11m children will die of cancer between now and 2050 without additional investment. The disease kills more than 100,000 children a year but 80 per cent of these cases are curable. Lowand middle-income countries where children have poor access to health services are disproportionately affected. (Lancet Oncology)

Climate change Heat stress, caused by the bodys inability to cool down properly through sweating, could affect more than 1.2bn people a year by 2100, says a new study more than four times the number affected today. Some want the WHO to declare climate change a global public health emergency. (Environmental Research Letters, BMJ)

Antibiotic alert A meta-study of antibiotic use shows three trends: city dwellers use more than those in rural areas; the elderly use more than the middle-aged, and usage decreases as education increases but only in rich countries. (International Journal of Hygiene and Environmental Health)

Coronavirus vaccine Seth Berkley, head of Gavi, the Vaccine Alliance, urges governments to set aside nationalism in the search for avaccine.(CBC, 13m)

The pandemic and the poorWhat does the coronavirus crisis mean for low-income countries and international development? A discussion with Amanda Glassman of the Center for Global Development.(UN Global Dispatches, 28m)

Urban healthHow do you build a healthy city? FT correspondents discuss initiatives in six cities, from tackling loneliness in Copenhagen to healthier eating in Tokyo.

Obamacare turns ten A discussion on the history, impact and prospects for the Affordable Care Act, which gave millions of Americans access to healthcare, but remains under threat. (Kaiser What the Health, 46m)

Epidemics in moviesWhat do films like Contagion tell us about societys view of epidemics? Some depict disease as a threat to society from outside, foreign forces, while others address threats to liberty, but both are linked to a breakdown in trust.(CDC Emerging Infectious Diseases, 32m)

April 7World Health Daycelebrating the work of nurses and midwives

April 14 FirstWorld Chagas Disease Day

April 19-20 G20 (virtual) meeting of health ministers, Riyadh

April 24-30 World Immunisation Week

April 25World Malaria Day

May 6 Next issue of FT Health

Contact Email us viahealth@ft.com, like us onFacebook and follow us on Twitter@fthealth andLinkedIn.

FT Health by email Register here to get FT Health in your inbox on the first Wednesday of each month.

Health at Work Join our quest to find Britains healthiest workplaces

Digital health Submit your ideasto the FT/Lancet Commission on how AI and digital health developments can benefit the worlds poorest.

FT resources You can find all FT in-depth health reports atFT Health Centre.

Coronavirus Business Update Sign upherefor our newsletter chronicling the epidemics impact on markets, global business, workplaces and our daily lives. The FT is offering a free 30-day trial to this email, which includes access to FT.com

Many short-term emergency measures will become a fixture of life. That is the nature of emergencies. They fast-forward historical processes, writesYuval Noah Hararion the world after coronavirus. The storm will pass. But the choices we make now could change our lives for years to come.

Read more:
FT Health: Coronavirus and the dangers of distraction - Financial Times

Read More...

Page 11234..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick